YntraDose (yttrium-90 microspheres) / BetaGlue Therapeutics - LARVOL DELTA

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) (The Manila Times) - "The clinical study is expected to begin enrolling patients in early 2026, with preliminary results expected by the end of the year. This early feasibility clinical investigation aims to assess the safety, usability and feasibility of YntraDose administration in patients with unresectable LA-PDAC, a disease with limited effective treatment options and a significant unmet medical need."

New trial • Pancreatic Ductal Adenocarcinoma